Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Clinical trial NCT05950308 · COMPLETED
Trial details
- NCT number
- NCT05950308
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-01-05
- Primary completion
- 2022-07-14
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.